Semax
| Clinical data | |
|---|---|
| Trade names | Semax |
| Other names | L-Methionyl-L-α-glutamylhistidyl-L-phenylalanyl-L-prolylglycyl-L-proline, (Pro8,Gly9,Pro10)ACTH-(4-10), H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, MEHFPGP, H-MEHFPGP-OH |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C37H51N9O10S |
| Molar mass | 813.93 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Semax (Russian: СЕМАКС), an abbreviation of "seven amino acids", Russian: СЕМь АминоКиСлот) is a medication which is used in Eastern Europe for the treatment of a broad range of conditions like brain trauma but predominantly for its claimed nootropic, neuroprotective, and neurorestorative effects.
The mechanism of action of Semax is unknown. It might interact with certain melanocortin receptors or inhibit enkephalinase enzymes. Chemically, Semax is a peptide and a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH).
Semax was first described in scientific literature in 1991. Although used as a prescription drug in Russia, Semax has not been evaluated, approved for use, or marketed in most other countries. The drug is widely sold by online vendors and used as a purported nootropic (cognitive enhancer).